Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $80M | $3M | $-5M | $10M | -17.6% | 104.9% | 20.4% |
| 2024 | $39M | $-1M | $-4M | $-9M | -15.7% | 23.3% | 308.4% |
| 2023 | $32M | $-0M | $-1M | $6M | -6.0% | 48.9% | -89.6% |
| 2022 | $21M | $-6M | $-9M | $2M | -69.0% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 79.95 |
| Operating Revenue | 79.95 |
| Cost Of Revenue | 37.21 |
| Gross Profit | 42.74 |
| Operating Expense | 43.58 |
| Research And Development | 7.76 |
| Selling General And Administration | 35.82 |
| Total Expenses | 80.79 |
| Operating Income | -0.84 |
| Total Operating Income As Reported | -0.84 |
| EBITDA | 3.20 |
| Normalized EBITDA | 3.20 |
| EBIT | -0.84 |
| Net Interest Income | -3.71 |
| Other Income Expense | - |
| Net Non Operating Interest Income Expense | -3.71 |
| Pretax Income | -4.56 |
| Tax Provision | 0.04 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -4.60 |
| Net Income From Continuing And Discontinued Operation | -4.60 |
| Net Income From Continuing Operation Net Minority Interest | -4.60 |
| Net Income | -4.60 |
| Net Income Common Stockholders | -4.60 |
| Net Income Including Noncontrolling Interests | -4.60 |
| Normalized Income | -4.60 |
| Diluted NI Availto Com Stockholders | -4.60 |
| Basic Average Shares | 26.91 |
| Diluted Average Shares | 26.91 |
| Reconciled Depreciation | 4.04 |
| Reconciled Cost Of Revenue | 37.21 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Special Income Charges | - |
| Other Special Charges | - |
| General And Administrative Expense | 35.82 |
| Other Gand A | 35.82 |
| Gain On Sale Of Ppe | - |
| Total Other Finance Cost | 3.71 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Eton Pharmaceuticals, Inc.this co. | ETON | $792M | -172.06 | 30.27 | -17.6% | 248.97 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $825M | 8.41 | 1.05 | 12.4% | 6.17 |
| Sana Biotechnology, Inc. | SANA | $824M | -3.37 | 5.12 | -151.8% | -4.31 |
| Replimune Group, Inc. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Esperion Therapeutics, Inc. | ESPR |
| - |
| - |
| - |
| - |
| - |
| - |
| $806M |
| - |
| - |
| 7.5% |
| 13.94 |
| Lumexa Imaging Holdings, Inc. | LMRI | $792M | -16.81 | 1.35 | -8.0% | 11.96 |
| Phathom Pharmaceuticals, Inc. | PHAT | $786M | -3.55 | -1.79 | 50.5% | -5.69 |
| Kura Oncology, Inc. | KURA | $779M | - | 4.47 | -160.0% | - |
| Geron Corporation | GERN | $776M | -9.30 | 3.44 | -37.0% | -16.53 |
| Peer Median | - | -3.46 | 1.96 | -22.5% | -3.31 | |